Modality
Fusion Protein
MOA
TYK2i
Target
CD20
Pathway
Lipid Met
DMDPsoriasisLN
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
Dec 2018
→ Jun 2025
Phase 2Current
NCT07024217
530 pts·Psoriasis
2018-12→2025-06·Completed
530 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0510mo agoPh2 Data· Psoriasis
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P2
Complet…
Catalysts
Ph2 Data
2025-06-05 · 10mo ago
Psoriasis
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07024217 | Phase 2 | Psoriasis | Completed | 530 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |